Latest On Rhythm Pharmaceuticals, Inc (RYTM):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-08 15:06 EST | News | Rhythm Pharma wins Canadian nod for weight loss therapy | N/A |  |
| 2023-05-03 02:24 EST | News | Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-03 02:24 EST | News | Rhythm Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call Presentation | N/A | |
| 2023-05-02 14:08 EST | News | Rhythm Pharmaceuticals reports misses Q1 top and bottom consensus; reaffirms FY23 outlook | N/A | |
| 2023-03-15 16:28 EST | News | Rhythm's Imcivree Warrants Caution Despite Clinical Progress | N/A | |
About Rhythm Pharmaceuticals, Inc (RYTM):
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. The company read more...was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
General
- Name Rhythm Pharmaceuticals, Inc
- Symbol RYTM
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 90
- Fiscal Year EndDecember
- IPO Date2017-10-05
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.rhythmtx.com
Valuation
- Price/Book (Most Recent Quarter) 7.86
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.93
- Next Year EPS Estimate -$2.44
- Next Quarter EPS Estimate $0.90
- Return on Assets -34%
- Return on Equity -60%
- Earnings Per Share -$3.34
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 1.25 billion
- EBITDA -120292000
- PE Ratio -11.14
- Analyst Target Price $46.25
- Book Value Per Share $3.77
Share Statistics
- Shares Outstanding 49.24 million
- Shares Float 36.87 million
- % Held by Insiders 347%
- % Held by Institutions 91.48%
- Shares Short 2.74 million
- Shares Short Prior Month 2.94 million
- Short Ratio 4.76
- Short % of Float 7%
- Short % of Shares Outstanding 5%
Technicals
- Beta 1.53
- 52 Week High $43.26
- 52 Week Low $13.09
- 50 Day Moving Average 28.41
- 200 Day Moving Average 27.57
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Rhythm Pharmaceuticals, Inc (RYTM) Dividend Calendar:
Rhythm Pharmaceuticals, Inc (RYTM) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Rhythm Pharmaceuticals, Inc (RYTM) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Rhythm Pharmaceuticals, Inc (RYTM) Chart:
Rhythm Pharmaceuticals, Inc (RYTM) News:
Below you will find a list of latest news for Rhythm Pharmaceuticals, Inc (RYTM) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Rhythm Pharmaceuticals, Inc (RYTM) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest RYTM Trades:
Rhythm Pharmaceuticals, Inc (RYTM) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-02 | 8-K (Current report) | |
| 2020-11-02 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-10-06 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-10-06 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-16 | 8-K (Current report) | |
| 2020-09-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-17 | CT ORDER (Confidential treatment order) | |
| 2020-08-13 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-03 | 8-K (Current report) | |
| 2020-08-03 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-07-21 | 8-K (Current report) | |
| 2020-07-21 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-21 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-30 | 4 (Statement of changes in beneficial ownership of securities) | |
Rhythm Pharmaceuticals, Inc (RYTM) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Rhythm Pharmaceuticals, Inc (RYTM). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 347%
Institutional Ownership: 9148%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-08-31 | Nithya Desikan | Chief Commercial Officer | Sell | 25,000.00 | 30.00 | 750,000.00 | 43,602.00 | |
| 2020-08-31 | Nithya Desikan | Chief Commercial Officer | Buy | 25,000.00 | 6.88 | 172,000.00 | 68,602.00 | |
| 2020-08-11 | Nithya Desikan | Chief Commercial Officer | Buy | 14,534.00 | 6.88 | 99,993.92 | 43,602.00 | |
| 2020-07-02 | RA CAPITAL MANAGEMENT, L.P. | 10% Share Holder | Sell | 44,153.00 | 22.04 | 972,968.75 | 5,140,408.00 | |
| 2020-07-01 | RA CAPITAL MANAGEMENT, L.P. | 10% Share Holder | Sell | 25,527.00 | 21.87 | 558,311.23 | 5,184,561.00 | |
| 2020-06-30 | RA CAPITAL MANAGEMENT, L.P. | 10% Share Holder | Sell | 61,901.00 | 22.15 | 1,371,237.14 | 5,210,088.00 | |
| 2020-06-29 | RA CAPITAL MANAGEMENT, L.P. | 10% Share Holder | Sell | 52,049.00 | 22.19 | 1,154,998.54 | 5,271,989.00 | |
| 2020-06-26 | Todd Foley | Director | Sell | 300.00 | 25.04 | 7,512.00 | 1,909,258.00 | |
| 2020-06-26 | RA CAPITAL MANAGEMENT, L.P. | 10% Share Holder | Sell | 86,706.00 | 23.31 | 2,020,848.07 | 5,324,038.00 | |
| 2020-06-25 | Todd Foley | Director | Sell | 17,947.00 | 25.41 | 456,033.27 | 1,909,558.00 | |
| 2020-06-25 | RA CAPITAL MANAGEMENT, L.P. | 10% Share Holder | Sell | 11,568.00 | 25.05 | 289,767.99 | 5,410,744.00 | |
| 2020-06-24 | Todd Foley | Director | Sell | 97,388.00 | 25.34 | 2,467,811.92 | 1,927,505.00 | |
| 2020-06-05 | Todd Foley | Director | Sell | 1,896.00 | 20.00 | 37,920.00 | 2,024,893.00 | |
| 2020-06-03 | Todd Foley | Director | Sell | 18,245.00 | 20.27 | 369,826.15 | 2,026,789.00 | |
| 2020-06-02 | Todd Foley | Director | Sell | 15,578.00 | 20.23 | 315,142.94 | 2,045,034.00 | |
| 2020-06-01 | Todd Foley | Director | Sell | 10,535.00 | 20.08 | 211,542.80 | 2,060,612.00 | |
| 2020-05-28 | Todd Foley | Director | Sell | 19,152.00 | 20.19 | 386,678.88 | 2,071,147.00 | |
| 2020-05-27 | Todd Foley | Director | Sell | 10,148.00 | 20.13 | 204,279.24 | 2,090,299.00 | |
| 2020-05-26 | Todd Foley | Director | Sell | 44,421.00 | 20.47 | 909,297.87 | 2,100,447.00 | |
| 2020-05-22 | Todd Foley | Director | Sell | 26,906.00 | 20.13 | 541,617.78 | 2,144,868.00 | |